Search Results
Aug 24, 2026, 08:15 ET BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) ("BrainStorm" or the "Company"), a developer of cell therapies for neurodegenerative diseases, today announced that members of its executive leadership
More news about: BrainStorm Cell Therapeutics Inc.
Aug 14, 2026, 16:00 ET BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended
More news about: BrainStorm Cell Therapeutics Inc.
Jul 28, 2026, 08:00 ET BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
NEW YORK, July 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced a major strategic
More news about: BrainStorm Cell Therapeutics Inc.
Jun 02, 2026, 09:00 ET BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
NEW YORK, June 2, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better
More news about: BrainStorm Cell Therapeutics Inc.
May 28, 2026, 07:45 ET BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the
More news about: BrainStorm Cell Therapeutics Inc.
May 19, 2026, 08:00 ET BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
NEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements
More news about: Brainstorm Cell Therapeutics Ltd.
May 15, 2026, 16:05 ET BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March
More news about: BrainStorm Cell Therapeutics Inc.
Mar 31, 2026, 16:01 ET BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidenceCompany highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteriaNEW
More news about: BrainStorm Cell Therapeutics Inc.
Feb 26, 2026, 06:22 ET Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a second definitive agreement
More news about: BrainStorm Cell Therapeutics Inc.
Feb 20, 2026, 06:00 ET Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a definitive agreement for a strategic
More news about: BrainStorm Cell Therapeutics Inc.
Dec 16, 2025, 11:53 ET Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Mesoblast Limited (NASDAQ: MESO), Lineage Cell Therapeutics, Inc. (NYSE-A: LCTX), and BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI).
More news about: Equity Insider
Nov 14, 2025, 16:30 ET BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September
More news about: BrainStorm Cell Therapeutics Inc.